Docoh
Loading...

INTI Inhibitor Therapeutics

HedgePath Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which discovers, develops and plans to commercialize therapeutics for patients with cancer. It also explores acquiring or licensing therapeutics addressing unmet needs and orphan indications beyond cancer. The company was founded on September 30, 1992 and is headquartered in Tampa, FL.

Company profile

Ticker
INTI
Exchange
CEO
Nicholas Jon Virca
Employees
Incorporated
Location
Fiscal year end
Former names
COMMONWEALTH BIOTECHNOLOGIES INC, HedgePath Pharmaceuticals, Inc.
SEC CIK
IRS number
541641133

INTI stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

26 Mar 21
13 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 75.06K 75.06K 75.06K 75.06K 75.06K 75.06K
Cash burn (monthly) (positive/no burn) 60.73K 18.58K 88.25K 5.55K 68.78K
Cash used (since last report) n/a 209.92K 64.22K 305.05K 19.18K 237.75K
Cash remaining n/a -134.86K 10.84K -229.99K 55.88K -162.69K
Runway (months of cash) n/a -2.2 0.6 -2.6 10.1 -2.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Jan 21 Mayne Pharma Ventures Pty Common Stock Other Aquire J No No 0 2,240,488 0 204,083,227
22 Dec 20 Garrison J. Hasara Common Stock Option Common Stock Grant Aquire A No No 0.031 125,000 3.88K 125,000
22 Dec 20 Ono Richard Dana Common Stock Option Common Stock Grant Aquire A No No 0.031 754,839 23.4K 754,839
22 Dec 20 Peattie Debra Common Stock Option Common Stock Grant Aquire A No No 0.031 580,646 18K 580,646
22 Dec 20 Martin Robert Daniel Common Stock Option Common Stock Grant Aquire A No No 0.031 754,839 23.4K 754,839

Financial report summary

?
Management Discussion
  • We are a pharmaceutical development company that is seeking to discover, develop and ultimately commercialize innovative therapeutics for patients with certain cancers and non-cancerous proliferation disorders. We also have explored and expect to continue to explore acquiring or licensing other innovative pre-clinical and clinical stage therapeutics addressing unmet needs and orphan indications for the treatment of cancer and other diseases.
  • Our current primary focus is on the development of therapies initially for prostate and lung cancers in the United States utilizing SUBA-Itraconazole, a patented, oral formulation of the currently marketed anti-fungal drug itraconazole to which we hold an exclusive U.S. license from our majority stockholder, Mayne Pharma, for certain cancers and non-cancerous proliferation disorders. We previously conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of Basal Cell Carcinoma Nevus Syndrome, and Mayne Pharma assumed control of the clinical and regulatory development of this indication in December 2018 as described elsewhere in this Report.
  • SUBA-Itraconazole was developed and is licensed to us by our majority stockholder Mayne Pharma under a supply and license agreement, originally dated September 3, 2013, and most recently amended and restated in December 2018. Mayne Pharma is an Australian specialty pharmaceutical company that develops and manufactures branded and generic products, which it distributes directly or through distribution partners and provides contract development and manufacturing services. In addition to being our licensor and supplier, under the Third Amended SLA and related agreements, Mayne Pharma holds a majority equity stake in our company and holds important rights with respect to our company, such as the right (in its discretion) to appoint and remove members of our Board of Directors.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Aid, amortized, bankrupt, Bayer, borrower, BRCA, capmatinib, Citibank, coordinating, darolutamide, default, discontinue, discontinued, discontinuing, downturn, drawdown, economy, FDC, forgivable, forgiven, inter, loan, Lynparza, Mayo, Notwithstanding, Nubeqa, Olaparib, page, pandemic, Paycheck, plaintiff, PPP, preceding, premium, prepay, prepayment, Prime, promissory, Provenge, recommence, reexamination, remotely, repayment, resume, retail, Rubraca, rucaparib, St, Tabrecta, twenty, validly, Valo, virtually, waste, week
Removed: concert, core, inInternal, JHU, kind, onForm, orin, principle, redeem, spearhead, theJournal, throughin, underRule, underSection, worked